PE20191661A1 - Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos - Google Patents
Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismosInfo
- Publication number
- PE20191661A1 PE20191661A1 PE2019001372A PE2019001372A PE20191661A1 PE 20191661 A1 PE20191661 A1 PE 20191661A1 PE 2019001372 A PE2019001372 A PE 2019001372A PE 2019001372 A PE2019001372 A PE 2019001372A PE 20191661 A1 PE20191661 A1 PE 20191661A1
- Authority
- PE
- Peru
- Prior art keywords
- tgfbeta1
- antibody
- isoform
- permisives
- inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- G01N33/575—
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/475—Assays involving growth factors
- G01N2333/495—Transforming growth factor [TGF]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
Abstract
Referido a un anticuerpo monoclonal o fragmento de union a antigeno del mismo, el cual se une a un complejo de proteinas del TGFbeta1(factor de crecimiento beta tipo 1) pro/latente; que comprende: un polipeptido de region variable de cadena pesada que es al menos 90% identico a la secuencia SEC ID N° 95, y un polipeptido de region variable de cadena ligera que es al menos 90% identico a la secuencia SEC ID N° 97. Ademas, dicho anticuerpo tiene secuencias de CDR opcionalmente con tres o menos sustituciones, o sin sustituciones. Dicho anticuerpo es un inhibidor de TGFbeta1 isoforma-especifico que ataca tanto a TGFbeta1 ECM (matriz extracelular)-asociado como a TGFbeta1 asociado a celula inmune pero no se dirige a TGFbeta2 o TGFbeta3 in vivo, siendo util para el tratamiento de cancer metastasico o alguna enfermedad asociada con la desregulacion de TGFbeta1. Tambien se refiere a una composicion farmaceutica que comprende dicho anticuerpo.
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762443615P | 2017-01-06 | 2017-01-06 | |
| US201762452866P | 2017-01-31 | 2017-01-31 | |
| US201762514417P | 2017-06-02 | 2017-06-02 | |
| US201762529616P | 2017-07-07 | 2017-07-07 | |
| US201762549767P | 2017-08-24 | 2017-08-24 | |
| US201762558311P | 2017-09-13 | 2017-09-13 | |
| US201762585227P | 2017-11-13 | 2017-11-13 | |
| US201762587964P | 2017-11-17 | 2017-11-17 | |
| US201762588626P | 2017-11-20 | 2017-11-20 | |
| PCT/US2018/012601 WO2018129329A1 (en) | 2017-01-06 | 2018-01-05 | ISOFORM-SPECIFIC, CONTEXT-PERMISSIVE TGFβ1 INHIBITORS AND USE THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20191661A1 true PE20191661A1 (es) | 2019-11-11 |
Family
ID=61198888
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2019001372A PE20191661A1 (es) | 2017-01-06 | 2018-01-05 | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180207267A1 (es) |
| EP (1) | EP3551658A1 (es) |
| JP (3) | JP7157744B2 (es) |
| KR (2) | KR20190098255A (es) |
| CN (2) | CN110382530A (es) |
| AU (2) | AU2018205231A1 (es) |
| BR (1) | BR112019013908A2 (es) |
| CA (1) | CA3049005A1 (es) |
| CL (1) | CL2019001874A1 (es) |
| CO (1) | CO2019007298A2 (es) |
| CR (1) | CR20190350A (es) |
| DO (1) | DOP2019000180A (es) |
| IL (2) | IL267790A (es) |
| MX (1) | MX2019008197A (es) |
| PE (1) | PE20191661A1 (es) |
| PH (1) | PH12019501575A1 (es) |
| WO (1) | WO2018129329A1 (es) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3365368B1 (en) | 2016-03-11 | 2023-05-17 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
| PE20191661A1 (es) * | 2017-01-06 | 2019-11-11 | Scholar Rock Inc | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos |
| US12358992B2 (en) | 2017-07-28 | 2025-07-15 | Scholar Rock, Inc. | LTBP complex-specific inhibitors of TGF-beta 1 and uses thereof |
| EP3694552A1 (en) | 2017-10-10 | 2020-08-19 | Tilos Therapeutics, Inc. | Anti-lap antibodies and uses thereof |
| EP4019046A1 (en) | 2018-07-11 | 2022-06-29 | Scholar Rock, Inc. | Isoform selective tgfbeta1 inhibitors and use thereof |
| US20210340238A1 (en) | 2018-07-11 | 2021-11-04 | Scholar Rock, Inc. | TGFß1 INHIBITORS AND USE THEREOF |
| SG11202013231SA (en) | 2018-07-11 | 2021-01-28 | Scholar Rock Inc | HIGH-AFFINITY, ISOFORM-SELECTIVE TGFß1 INHIBITORS AND USE THEREOF |
| US12331320B2 (en) | 2018-10-10 | 2025-06-17 | The Research Foundation For The State University Of New York | Genome edited cancer cell vaccines |
| CN113164780A (zh) | 2018-10-10 | 2021-07-23 | 泰洛斯治疗公司 | 抗lap抗体变体及其用途 |
| EP3689905A3 (en) | 2019-01-30 | 2021-02-24 | Scholar Rock, Inc. | Ltbp complex-specific inhibitors of tgf-beta and uses thereof |
| CN113906298B (zh) * | 2019-03-27 | 2024-12-20 | 新加坡保健服务集团有限公司 | 对腹膜癌扩散具有治疗意义的生物标志物 |
| WO2020206055A1 (en) * | 2019-04-02 | 2020-10-08 | Yale University | Methods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof |
| AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
| CN120022360A (zh) | 2019-08-28 | 2025-05-23 | 中外制药株式会社 | 跨物种抗潜伏TGF-β1抗体和使用方法 |
| WO2021097039A1 (en) | 2019-11-15 | 2021-05-20 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
| IL294650A (en) | 2020-01-11 | 2022-09-01 | Scholar Rock Inc | Tgfbeta inhibitors and use thereof |
| US20230050148A1 (en) | 2020-01-11 | 2023-02-16 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| MX2022011892A (es) | 2020-03-26 | 2022-10-18 | Univ Vanderbilt | Anticuerpos monoclonales humanos dirigidos contra el coronavirus 2 del sindrome respiratorio agudo grave (sars-cov-2). |
| WO2021195485A1 (en) * | 2020-03-27 | 2021-09-30 | Vanderbilt University | Human monoclonal antibodies to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) |
| BR112022021789A2 (pt) | 2020-04-27 | 2023-03-07 | Twist Bioscience Corp | Bibliotecas de ácido nucléico variantes para coronavírus |
| TWI838626B (zh) | 2020-06-03 | 2024-04-11 | 美商基利科學股份有限公司 | Lpa受體拮抗劑及其用途 |
| WO2021247215A1 (en) | 2020-06-03 | 2021-12-09 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
| BR112023010168A2 (pt) * | 2020-12-02 | 2024-02-06 | Shanghai Henlius Biotech Inc | Anticorpos anti-garp/tgfbeta e métodos de uso |
| CN114957476A (zh) * | 2021-02-23 | 2022-08-30 | 复旦大学 | 一种半胱氨酸工程化的结合人5t4的全人源纳米抗体 |
| WO2022204581A2 (en) | 2021-03-26 | 2022-09-29 | Scholar Rock, Inc. | Tgf-beta inhibitors and use thereof |
| TWI818538B (zh) | 2021-05-11 | 2023-10-11 | 美商基利科學股份有限公司 | Ｌｐａ受體拮抗劑及其用途 |
| JP7691522B2 (ja) | 2021-05-13 | 2025-06-11 | ギリアード サイエンシーズ， インコーポレイテッド | Ｌｐａ受容体アンタゴニスト及びそれらの使用 |
| EP4348260A2 (en) | 2021-06-03 | 2024-04-10 | Scholar Rock, Inc. | Tgf-beta inhibitors and therapeutic use thereof |
| US20240301073A1 (en) | 2021-07-14 | 2024-09-12 | Scholar Rock, Inc. | LTBP COMPLEX-SPECIFIC INHIBITORS OF TGFb1 AND USES THEREOF |
| KR20240115978A (ko) | 2021-12-08 | 2024-07-26 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
| CA3237577A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
| JP2024546851A (ja) | 2021-12-22 | 2024-12-26 | ギリアード サイエンシーズ， インコーポレイテッド | Ｉｋａｒｏｓジンクフィンガーファミリー分解剤及びその使用 |
| PL4245756T3 (pl) | 2022-03-17 | 2025-02-17 | Gilead Sciences, Inc. | Środki degradujące palec cynkowy z rodziny ikaros i ich zastosowania |
| CN119255993A (zh) | 2022-03-22 | 2025-01-03 | 奥托泰利克生物公司 | 噻唑衍生物化合物及其用途 |
| CN120225509A (zh) | 2022-12-22 | 2025-06-27 | 吉利德科学公司 | Prmt5抑制剂及其用途 |
| WO2024187051A1 (en) | 2023-03-07 | 2024-09-12 | Scholar Rock, Inc. | Tgf-beta inhibitors for use for treating resistant or unresponsive cancer in patients |
| KR20250175331A (ko) | 2023-04-21 | 2025-12-16 | 길리애드 사이언시즈, 인코포레이티드 | Prmt5 억제제 및 이의 용도 |
| US20250154172A1 (en) | 2023-11-03 | 2025-05-15 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
| US20250230168A1 (en) | 2023-12-22 | 2025-07-17 | Gilead Sciences, Inc. | Azaspiro wrn inhibitors |
| CN117721079B (zh) * | 2024-01-26 | 2025-03-11 | 广东壹加再生医学研究院有限公司 | 一种促进nk细胞抗肿瘤活性的培养基及培养方法 |
| WO2025240343A1 (en) | 2024-05-13 | 2025-11-20 | Scholar Rock, Inc. | Tgf-beta inhibitors for treating cancer |
| WO2025245003A1 (en) | 2024-05-21 | 2025-11-27 | Gilead Sciences, Inc. | Prmt5 inhibitors and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
| GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
| JPS6147500A (ja) | 1984-08-15 | 1986-03-07 | Res Dev Corp Of Japan | キメラモノクロ−ナル抗体及びその製造法 |
| EP0173494A3 (en) | 1984-08-27 | 1987-11-25 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric receptors by dna splicing and expression |
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DE68927933T2 (de) | 1988-09-02 | 1997-08-14 | Dyax Corp | Herstellung und auswahl von rekombinantproteinen mit verschiedenen bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| CA2109602C (en) | 1990-07-10 | 2002-10-01 | Gregory P. Winter | Methods for producing members of specific binding pairs |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2405246A1 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with alterred binding properties |
| ATE363532T1 (de) | 1991-03-01 | 2007-06-15 | Dyax Corp | Verfahren zur herstellung bindender miniproteine |
| CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5786464C1 (en) | 1994-09-19 | 2012-04-24 | Gen Hospital Corp | Overexpression of mammalian and viral proteins |
| AU729406B2 (en) | 1996-03-28 | 2001-02-01 | Johns Hopkins University, The | Soluble divalent and multivalent heterodimeric analogs of proteins |
| US6114148C1 (en) | 1996-09-20 | 2012-05-01 | Gen Hospital Corp | High level expression of proteins |
| US6914128B1 (en) | 1999-03-25 | 2005-07-05 | Abbott Gmbh & Co. Kg | Human antibodies that bind human IL-12 and methods for producing |
| US6492497B1 (en) | 1999-04-30 | 2002-12-10 | Cambridge Antibody Technology Limited | Specific binding members for TGFbeta1 |
| JP4955185B2 (ja) | 2000-06-29 | 2012-06-20 | アボット・ラボラトリーズ | 二重特異性抗体ならびに作製方法および使用方法 |
| GB0230202D0 (en) * | 2002-12-27 | 2003-02-05 | Domantis Ltd | Ligand |
| AR045563A1 (es) * | 2003-09-10 | 2005-11-02 | Warner Lambert Co | Anticuerpos dirigidos a m-csf |
| ES2905923T3 (es) | 2005-02-08 | 2022-04-12 | Genzyme Corp | Anticuerpos de TGFbeta |
| HUE041818T2 (hu) * | 2007-03-22 | 2019-05-28 | Biogen Ma Inc | Kötõ proteinek, beleértve az antitesteket, CD154-et specifikusan kötõ antitest származékokat és antitest fragmenseket is, és alkalmazásaik |
| PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
| US20100260668A1 (en) | 2008-04-29 | 2010-10-14 | Abbott Laboratories | Dual Variable Domain Immunoglobulins and Uses Thereof |
| RU2010153578A (ru) | 2008-06-03 | 2012-07-20 | Эбботт Лэборетриз (Us) | Иммуноглобулины с двойными вариабельными доменами и их применение |
| JO3096B1 (ar) * | 2008-11-07 | 2017-03-15 | Imclone Llc | الأجسام المضادة لمستقبل ii مضاد tgfb |
| WO2011102483A1 (ja) * | 2010-02-19 | 2011-08-25 | 独立行政法人理化学研究所 | ヒトTGF-βのLAPに結合する抗体 |
| UY33421A (es) | 2010-06-03 | 2011-12-30 | Glaxo Wellcome House | Proteinas de union al antígeno humanizados |
| TW201527322A (zh) * | 2011-02-08 | 2015-07-16 | Abbvie Inc | 骨關節炎及疼痛之治療 |
| LT2714735T (lt) * | 2011-06-03 | 2021-12-10 | Xoma Technology Ltd. | Tgf beta specifiniai antikūnai |
| EP2776467A1 (en) * | 2011-11-08 | 2014-09-17 | Pfizer Inc | Methods of treating inflammatory disorders using anti-m-csf antibodies |
| HUE038570T2 (hu) | 2011-11-14 | 2018-10-29 | Regeneron Pharma | Készítmények és eljárások izomtömeg és izomerõ növelésére GDF8 és/vagy aktivin A specifikus antagonizálásával |
| US9518112B2 (en) | 2012-03-08 | 2016-12-13 | Ludwig Institute For Cancer Research Ltd | TGF-β1 specific antibodies and methods and uses thereof |
| DK2981822T3 (da) * | 2013-05-06 | 2020-12-07 | Scholar Rock Inc | Sammensætninger og fremgangsmåder til vækstfaktormodulation |
| WO2015171691A2 (en) * | 2014-05-06 | 2015-11-12 | Scholar Rock, Inc. | Compositions and methods for growth factor modulation |
| CN107530423B (zh) * | 2015-01-14 | 2022-04-05 | 布里格姆及妇女医院股份有限公司 | 用抗lap单克隆抗体治疗癌症 |
| EP3365368B1 (en) | 2016-03-11 | 2023-05-17 | Scholar Rock, Inc. | Tgfbeta1-binding immunoglobulins and use thereof |
| PE20191661A1 (es) * | 2017-01-06 | 2019-11-11 | Scholar Rock Inc | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos |
-
2018
- 2018-01-05 PE PE2019001372A patent/PE20191661A1/es unknown
- 2018-01-05 KR KR1020197022663A patent/KR20190098255A/ko not_active Ceased
- 2018-01-05 WO PCT/US2018/012601 patent/WO2018129329A1/en not_active Ceased
- 2018-01-05 MX MX2019008197A patent/MX2019008197A/es unknown
- 2018-01-05 CN CN201880015969.2A patent/CN110382530A/zh active Pending
- 2018-01-05 CN CN202310792211.2A patent/CN117398457A/zh active Pending
- 2018-01-05 AU AU2018205231A patent/AU2018205231A1/en not_active Abandoned
- 2018-01-05 CR CR20190350A patent/CR20190350A/es unknown
- 2018-01-05 EP EP18705030.7A patent/EP3551658A1/en active Pending
- 2018-01-05 US US15/863,564 patent/US20180207267A1/en not_active Abandoned
- 2018-01-05 BR BR112019013908-7A patent/BR112019013908A2/pt unknown
- 2018-01-05 KR KR1020247030136A patent/KR20240137126A/ko not_active Ceased
- 2018-01-05 CA CA3049005A patent/CA3049005A1/en active Pending
- 2018-01-05 JP JP2019536919A patent/JP7157744B2/ja active Active
-
2019
- 2019-03-22 US US16/361,486 patent/US20190209682A1/en not_active Abandoned
- 2019-07-02 IL IL267790A patent/IL267790A/en unknown
- 2019-07-03 PH PH12019501575A patent/PH12019501575A1/en unknown
- 2019-07-05 DO DO2019000180A patent/DOP2019000180A/es unknown
- 2019-07-05 CL CL2019001874A patent/CL2019001874A1/es unknown
- 2019-07-08 CO CONC2019/0007298A patent/CO2019007298A2/es unknown
-
2022
- 2022-10-07 JP JP2022162088A patent/JP2022188226A/ja active Pending
-
2023
- 2023-07-11 IL IL304416A patent/IL304416A/en unknown
- 2023-08-01 US US18/363,435 patent/US20240016928A1/en active Pending
-
2024
- 2024-10-01 JP JP2024172672A patent/JP2025000891A/ja active Pending
-
2025
- 2025-05-16 AU AU2025203555A patent/AU2025203555A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| IL267790A (en) | 2019-09-26 |
| JP2020503362A (ja) | 2020-01-30 |
| CO2019007298A2 (es) | 2019-07-31 |
| US20240016928A1 (en) | 2024-01-18 |
| WO2018129329A1 (en) | 2018-07-12 |
| CN110382530A (zh) | 2019-10-25 |
| JP7157744B2 (ja) | 2022-10-20 |
| CL2019001874A1 (es) | 2019-12-06 |
| AU2025203555A1 (en) | 2025-06-05 |
| DOP2019000180A (es) | 2019-09-15 |
| KR20190098255A (ko) | 2019-08-21 |
| KR20240137126A (ko) | 2024-09-19 |
| CR20190350A (es) | 2019-11-15 |
| BR112019013908A2 (pt) | 2020-02-04 |
| MX2019008197A (es) | 2019-09-11 |
| CA3049005A1 (en) | 2018-07-12 |
| JP2022188226A (ja) | 2022-12-20 |
| IL304416A (en) | 2023-09-01 |
| PH12019501575A1 (en) | 2019-11-04 |
| US20190209682A1 (en) | 2019-07-11 |
| CN117398457A (zh) | 2024-01-16 |
| EP3551658A1 (en) | 2019-10-16 |
| AU2018205231A1 (en) | 2019-07-18 |
| US20180207267A1 (en) | 2018-07-26 |
| JP2025000891A (ja) | 2025-01-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20191661A1 (es) | Inhibidores de tgf beta1 isoforma-especificos contexto-permisivos y uso de los mismos | |
| GT201700162A (es) | Anticuerpos anti-cd3, anticuerpos anti-cd123 y anticuerpos biespecíficos que se unen específicamente a cd3 y/o cd123 | |
| CL2019000760A1 (es) | Tratamiento de migraña refractaria | |
| PE20150002A1 (es) | Anticuerpos anti-fcrn | |
| PE20130207A1 (es) | Anticuerpos antagonistas de lrp6 (proteina relacionada con lipoproteinas de baja densidad 6) y composiciones | |
| CL2016003346A1 (es) | Anticuerpos anti-tau humanizados | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| PE20210652A1 (es) | Moleculas de union a antigeno dirigidas a her2 que comprenden 4-1bbl | |
| MX377716B (es) | Moduladores de aplnr y usos de estos. | |
| PE20160690A1 (es) | Anticuerpos anti-cd134 (ox40) humanizados y usos de los mismos | |
| MX2017011534A (es) | Metodos para reducir los niveles de suero de agentes que contienen fc que usan antagonistas de fcrn. | |
| CL2017000250A1 (es) | Anticuerpo monoclonal anti-ctla4 o su fragmento de unión a antígeno, una composición farmacéutica y uso | |
| MX2021005048A (es) | Anticuerpos anti-ctla4, fragmentos de anticuerpos, sus inmunoconjugados y usos. | |
| CU24568B1 (es) | Anticuerpo inhibidor de masp-3 | |
| PE20141787A1 (es) | Composiciones anti-cgrp y uso de las mismas | |
| CL2015001895A1 (es) | Anticuerpos que se unen al tl1a y sus usos | |
| CL2012002433A1 (es) | Anticuerpo aislado o fragmento inmunoreactivo del mismo que comprende un dominio variable que se une específicamente a un dominio extracelular del receptor b7-h3; ácido nucleico que lo codifica; hibridoma que lo secreta; reactivo de redireccionamiento de doble afinidad (dart) que lo comprende; composición farmacéutica que lo comprende; y su uso para tratar cáncer. | |
| ES2584956T3 (es) | Anticuerpos anti-CD40 y usos de los mismos | |
| CL2020002600A1 (es) | Anticuerpo anti-muerte programada-ligando 1 y su uso | |
| PE20110306A1 (es) | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) | |
| EA201491599A1 (ru) | Антитела к матриксной металлопротеиназе 9 | |
| PE20120902A1 (es) | Anticuerpos anti-egfl7 humanizados | |
| MX2020013606A (es) | Constructos de anticuerpos multiespecificos. | |
| PE20201171A1 (es) | Anticuerpos de cadena pesada que se unen a cd22 | |
| PE20230381A1 (es) | Proteina de union a rgma |